benzyl N-[1-[4,5-dihydroxy-6-(phenethylcarbamoyl)pyrimidin-2-yl]-1-methyl-ethyl]carbamate | 1415000-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl N-[1-[4,5-dihydroxy-6-(phenethylcarbamoyl)pyrimidin-2-yl]-1-methyl-ethyl]carbamate
• 英文别名: benzyl N-[2-[5-hydroxy-6-oxo-4-(2-phenylethylcarbamoyl)-1H-pyrimidin-2-yl]propan-2-yl]carbamate
• CAS: 1415000-12-2
• 化学式: C₂₄H₂₆N₄O₅
• 分子量: 450.494
• InChiKey: UJFIHKOIRDOYRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (1-氰基-1-甲基乙基)氨基甲酸苄酯 在 羟胺 作用下， 以 甲醇 、 乙醇 、 正庚烷 、 水 、 异丙醇 为溶剂， 反应 23.83h， 生成 benzyl N-[1-[4,5-dihydroxy-6-(phenethylcarbamoyl)pyrimidin-2-yl]-1-methyl-ethyl]carbamate
  参考文献：
  名称：

  Structural modifications of 5,6-dihydroxypyrimidines with anti-HIV activity

  摘要：

  A series of 5,6-dihydroxypyrimidine analogs were synthesized and evaluated for their anti-HIV activity in vitro. Among all of the analogs, several compounds exhibited significant anti-HIV activity, especially 1b and 1e, which showed the most potent anti-HIV activity with EC50 values of 0.14 and 0.15 mu M, and TI (therapeutic index) values of >300 and >900, respectively. Further docking studies revealed that the representative compounds 1e and 3a could meet the HIV-1 integrase inhibition minimal requirements of a chelating domain (two metal ions) and an aromatic domain (pi-pi stacking interactions). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.070

文献信息

• Structural modifications of 5,6-dihydroxypyrimidines with anti-HIV activity
  作者：Di-Liang Guo、Xing-Jie Zhang、Rui-Rui Wang、Yu Zhou、Zeng Li、Jin-Yi Xu、Kai-Xian Chen、Yong-Tang Zheng、Hong Liu

  DOI：10.1016/j.bmcl.2012.09.070

  日期：2012.12

  A series of 5,6-dihydroxypyrimidine analogs were synthesized and evaluated for their anti-HIV activity in vitro. Among all of the analogs, several compounds exhibited significant anti-HIV activity, especially 1b and 1e, which showed the most potent anti-HIV activity with EC50 values of 0.14 and 0.15 mu M, and TI (therapeutic index) values of >300 and >900, respectively. Further docking studies revealed that the representative compounds 1e and 3a could meet the HIV-1 integrase inhibition minimal requirements of a chelating domain (two metal ions) and an aromatic domain (pi-pi stacking interactions). (C) 2012 Elsevier Ltd. All rights reserved.